Kim Kardashian is back on social media plugging for pharma. This time, the FDA might like her Instagram post better, but Instagram followers weren't so…

After a big slowdown in 2016, FDA new drug approvals got off to a hot start in 2017.

Roche’s checkpoint inhibitor Tecentriq, which won its initial approval as a treatment for bladder cancer, has now notched an approval to treatment for advanced…

Pharma has come a long way on patient centricity. Regulators, though? Not so much, Treato's CEO says.

Novartis loses Gilenya patent appeal, clearing way for early copies of the $3 billion multiple sclerosis med.

India’s Indico Remedies has had a sterile injectables plant blasted in an FDA warning letter for its laissez-faire approach to dealing with consumer complaints.

Maryland lawmakers have passed a bill aimed at taking on “unconscionable” pricing practices, but the industry still hopes to derail it.

Bristol-Myers Squibb’s Opdivo hasn’t even won marketing approval for head and neck cancer in England and Wales yet, but NICE is already shutting it out.

Teva contends that Mexican generics buy Rimsa sold defective, illegal products and lied about it. But a new memo from Mexico’s drug regulator doesn't help…